Which psychedelic clinical trials are actually recruiting?

The number that should be said out loud first

Of the 254 registered clinical trials currently in this tracker, 8 mention DMT or dimethyltryptamine in the trial title. Psilocybin appears in 127. Ketamine or esketamine in 65. MDMA in 29. LSD in 6. Ayahuasca in 3. Ibogaine in 1. Mescaline in none.

That is a title-string count rather than a curated compound field, so treat it as approximate at the edges. The shape is not approximate. The compound this project is named after is roughly three percent of the registered pipeline. Psilocybin is half of it.

If you came here expecting a site about DMT to tell you that DMT research is surging, that is not what the register says. Publishing the number that undercuts your own topic is the only way the other numbers on this site are worth anything.

What is in the tracker

As of 25 July 2026 the tracker holds 266 approved records:

• 254 registered clinical trials. Every one carries a ClinicalTrials.gov NCT number, so every claim on those pages resolves to a primary source you can check without us.
• 12 non-registered records: 9 citizen-science experiments, 2 items known only from podcast mentions, and 1 retreat-based experiment. None of these are registered trials. They are kept in their own class, marked as such, and deliberately left unlinked where no verifiable source exists. They are visible because suppressing them would be dishonest, and they are labelled because promoting them would be worse.

Status of the 266

| Status | Count | |---|---| | Recruiting | 153 | | Planned | 52 | | Active, not recruiting | 25 | | Completed | 23 | | Unknown | 7 | | Enrolling by invitation | 3 | | Suspended | 2 | | Terminated | 1 |

The headline for anyone actually looking for a study to join: 153 recruiting, plus 3 more enrolling by invitation. The headline for anyone assessing the state of the science is different, and it is in the next table.

Phase distribution, and the bottleneck it exposes

| Phase | Count | |---|---| | Phase 2 | 96 | | Phase 1 | 52 | | Not labelled | 48 | | Early Phase 1 | 18 | | Phase 1 / Phase 2 | 18 | | Phase 3 | 18 | | Phase 4 | 13 | | Phase 2 / Phase 3 | 3 |

Phase 2 outnumbers Phase 3 by more than five to one.

Phase 2 asks whether a signal exists in a modest sample. Phase 3 asks whether that signal survives a large, confirmatory, regulator-facing trial. A field with 96 Phase 2 studies and 18 Phase 3 studies is a field that has generated an enormous amount of promising early data and has not yet converted much of it into the kind of evidence that changes standard of care.

That is not a scandal and it is not a takedown. Phase 2 is where a young field is supposed to be crowded. It does mean that anyone reading "breakthrough" headlines should know that most of what is being reported comes from the wide end of the funnel, where effects are routinely larger than they turn out to be later. Read the phase before you read the press release.

Note also the 48 records with no phase label. Many observational and mechanistic studies carry no phase at all, so a blank is not a red flag by itself. It is a reason not to quote a phase distribution to three decimal places.

A sample of what is recruiting

Drawn from the recruiting Phase 2 set, unedited:

• Set and setting, translational study in healthy volunteers. A 2 x 2 factorial, double-blind randomised trial, Robin Carhart-Harris. NCT06626139. Notable because it treats context itself as the variable rather than as an uncontrolled background condition.
• MDMA-assisted therapy for PTSD in U.S. veterans, dose optimisation. Bronx VA Medical Center. NCT06418178.
• Psilocybin microdosing plus psychotherapy in treatment-resistant depression, double-blind feasibility. Beersheva Mental Health Center. NCT07183748.
• Psilocybin for co-occurring alcohol use disorder and PTSD in military veterans and first responders. NCT06853912.
• Psilocybin as an adjunct for opioid use disorder in patients who continue illicit use despite methadone adherence. NYU Langone Health. NCT06796062.
• Group retreat psilocybin therapy for cancer-related anxiety and depression, Phase 2a. University of Washington. NCT07336238.
• Psilocybin oral solution in generalised anxiety disorder, placebo-controlled Phase 2a. Queen's University. NCT06969170.

Every one of these resolves to a public registry record. Nothing above is an endorsement, an eligibility assessment, or an invitation. Recruiting status changes without notice and the registry entry is authoritative, not this page.

What this tracker is not, and where it is currently weak

Two disclosures, because a page about evidence quality that hides its own is worthless.

It is a mirror, not a source. Registered trials are ingested from ClinicalTrials.gov on a weekly schedule. Between ingests the register moves and we do not. Always confirm status against the registry record before acting on anything here.

The detail pages inherit the register's gaps. After a backfill from the source API, every registered record here now carries the registry's own eligibility text and summary rather than text we composed. The gaps that remain are the register's: 78 of the 254 records name no principal investigator, and 33 carry only a short description. Where a field on a detail page is empty, the ingest found nothing to put there. We would rather show an empty field than fill it with a guess.

If you are considering joining a study

Screening exists for a reason and it is not a formality. Trials in this space commonly exclude for personal or family history of psychosis or bipolar disorder, for specific cardiac conditions, and for a range of interacting medications, particularly serotonergic ones. That screening is a safety mechanism, not an obstacle to be worked around, and the exclusion criteria in these protocols were written from real adverse outcomes.

Talk to the study team and to your own clinician. Contact details are on the registry record, which is one click from every trial page here.